QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF

• US 20080206161A1
• Filed: 01/25/2008
• Published: 08/28/2008
• Est. Priority Date: 10/25/2002
• Status: Abandoned Application

• Current Assignee: Foamix Pharmaceuticals, Ltd. (VYNE Therapeutics, Inc.)
• Original Assignee: Foamix Pharmaceuticals, Ltd. (VYNE Therapeutics, Inc.)
• Inventors: TAMARKIN, Dov, BERMAN, Tal, FRIEDMAN, Doron, EINI, Meir, SCHUZ, David
• Application Number:
  US12/020,381
• Publication Number:
  US 20080206161A1
• Time in Patent Office: Days
• US Class Current: 424/45
• CPC Class Codes: A01N 25/16 Foams
• CPC Class Codes: A01N 53/00 Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61K 9/122 Foams; Dry foams edible foams A61K9/0056
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to an emulsion steroid composition as a foamable vehicle in which the vehicle is stable or stabilized by the presence of at least one quiesence agent; therapeutical kit containing such composition; to methods of treatment using such composition; to methods of enhancing the stability of such composition.

Claims

1. A storable foamable emulsion composition adapted for delivery of an active pharmaceutical ingredient (API) to a delivery site in a subject, the composition comprising:

a) at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight;

b) at least one surface-active agent at a concentration of about 0.01% to about 5% by weight;

c) at least one polymeric agent selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, each in a concentration of about 0.01% to about 5% by weight;

d) water;

e) an effective amount of at least one API selected from the group consisting of a steroid, a steroid derivative, and combinations thereof;

f) optionally, a further active agent; and

g) a propellant at a concentration of about 3% to about 25% by weight of the total foamable composition,

wherein, at ambient temperature, the storable foamable emulsion composition is shakable, is resistant to centrifugation at about 3000 rpm for about 10 min, is substantially devoid of crystals, is resistant to at least one freeze-thaw cycle and does not phase separate within at least about one month;

wherein the at least one API remains chemically stable for at least about one month; and

wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam having an average bubble size range of about 30 to about 250 micron.

2. The storable foamable emulsion composition of claim 1, wherein when compressed between two surfaces a negative adhesion force is required to effect their separation.

3. The storable foamable emulsion composition of claim 1, wherein the at least one API is contained in a Trapsome.

4. The storable foamable emulsion composition of claims 1, 2 and 3, wherein the API is selected from the group consisting of:

i. a steroid compound containing a cyclopenta[a]phenanthrene skeleton;

ii. a steroid compound containing a cyclopenta[a]phenanthrene skeleton carrying one or more functional groups selected from halogens, alkyl groups, aryl groups, benzyl groups, carboxy groups and alkoxy groups;

iii. a steroid compound selected from the families of (a) cardanolides, (b) bufanolides, (c) spirostans, (d) furostans, (e) steroid alkaloids, (f) steroid lactones, (g) oxo-steroids, (h) steroid-alcohols and (i) steroid-amines;

iv. a steroid compound, where one or more of the cyclopenta[a]phenanthrene rings is contracted by loss of an unsubstituted methylene group;

v. a steroid compound, where one or more of the cyclopenta[a]phenanthrene rings is expanded by inclusion of a methylene group;

vi. a steroid compound containing a cyclopenta[a]phenanthrene skeleton and a carbocyclic or heterocyclic ring component fused to it;

vii. a compound, wherein two or more steroid molecules are linked together covalently;

viii. a compound selected from the group consisting of 5-pregnane, 5β

-pregnane, 5α

-cholane (allocholane), 5β

-cholane, 5β

-cholestane, 5β

-cholestane, 5α

-ergostane, 5-ergostane, 5α

-campestane, 5-campestane, 5α

-poriferastane, 5β

-poriferastane, 5α

-stigmastane, 5-stigmastane, 5α

-gorgostaneacrihellin, actodigin, alfacalcidol, aldosterone, androsterone, betamethasone, brassinolide, calcidiol, calciol, calcitriol, canrenone, clomegestone, cholesterol, cholic acid, corticosterone, cortisol, cortisol acetate, cortisone, cortisone acetate, cyproterone, deoxycorticosterone, dexamethasone, disogluside, ecdysone, ercalciol, ergosterol, estradiol, estriol, estrone, ethinylestradiol, fluazacort, fluocortin, fusidic acid, gestrinone, gonane, halometasone, hydrocortisone, lanosterol, lithocholic acid, mebolazine, medroxyprogesterone, meproscillarin, mespirenone, mestranol, naflocort, norenthisterone, norgesterone, norgestrel, oxandrolone, oxymetholone, pancuronium bromide, prednisolone, prednisone, progesterone, proscillardin, pseudotigogenin, roxibolone, sarsasapogenin, smilagenin, spironolactone, timobesone, testosterone, tigogenin triamcinolone, ursodeoxycholic acid;

ix. an anti-inflammatory steroid;

x. a steroid possessing immunomodulating and/or anti-inflammatory properties;

xi. a steroid, selected from the group of low-potency anti-inflammatory steroids, medium potency anti-inflammatory steroids and high potency anti-inflammatory steroids;

xii. an anti-inflammatory steroid, selected from the group consisting of hydrocortisone, hydrocortisone acetate, desonide, betamethasone valerate, clobetasone-17-butyrate, flucinonide, fluocinolone acetonide, alcometasone dipropionate, mometasone furoate, prednicarbate, triamcinolone acetonide, betamethasone-17-benzoate, methylprednisolone aceponate, betamethasone dipropionate, halcinonide, triamcinolone acetonide, halobetasol, clobetasol-17-propionate;

xiii. a steroid that positively affects the McKenzie vasoconstrictor assay;

xiv. a steroid hormone;

xv. a steroid hormone, selected from the group consisting of an androgen, an estrogen and a progestogen;

xvi. an androgen, selected from the group consisting of testosterone, testosterone cipionate, testosterone decanoate, testosterone enantate, testosterone isocaproate, testosterone phenylpropionate, testosterone propionate, testosterone undecylate, 5α

-dihydrotestosterone, dehydroepiandrosterone (also termed prasterone and DHEA), androstenedione, androstanediol, androsterone, androstenolone, prasterone enantate, prasterone sodium sulfate, ormeloxifene, mesterolone, fluoxymesterone, methyltestosterone, gestrinone, delmadinone, delmadinone acetate, chlormadinone, chlormadinone acetate, danazol and testolactone;

xvii. an estrogen selected from the group consisting of estradiol, estradiol benzoate, estradiol cipionate, estradiol dipropionate, estradiol enantate, estradiol hexahydrobenzoate, estradiol phenylpropionate, estradiol valerate, polyestradiol phosphate, estriol, estriol sodium succinate, estriol succinate, polyestriol phosphate, quinestradol, ethinylestradiol, estrapronicate, mestranol, estrapronicate and equilin;

xviii. a progestogen, selected from the group consisting of progesterone, norethisterone, norethisterone acetate, norethisterone enantate, medroxyprogesterone acetate, delmadinone acetate, flugestone acetate, dydrogesterone, desogestrel, norgestrel, levonorgestrel, dydrogesterone, gestodene, chlormadinone acetate, dienogest, drospirenone, lynestrenol, tybolone, cyproterone acetate, megestrol acetate, nomegestrol acetate;

xix. an inhibitor of a steroid hormone;

xx. an inhibitor of a steroid hormone selected from the group consisting of finasteride, dutasteride and spironolactone;

xxi. a vitamin D;

xxii. a steroid that exhibits qualitatively the biological activity of calciol;

xxiii. a vitamin D selected from the group consisting of cholecalciferol, 25-hydroxycholecalciferol, 1α

,25-dihydroxycholecalciferol, ergocalciferol, 1α

,25-dihydroxyergocalciferol, 22,23-dihydroergocalciferol, 1,24,25-trihydroxycholecalciferol, previtamin D3, tachysterol3 (also termed tacalciol);

xxiv. a vitamin D3 analogue;

xxv. isovitamin D3, dihydrotachysterol3, (1S)-hydroxycalciol, (24R)-hydroxycalcidiol, 25-fluorocalciol, ercalcidiol, ertacalciol, (5E)-isocalciol, 22,23-dihydroercalciol, (24S)-methylcalciol, (5E)-(10S)-10,19-dihydroercalciol, (24S)-ethylcalciol and (22E)-(24R)-ethyl-22,23-didehydrocalciol;

xxvi. a vitamin D3 analogue selected from the group consisting of calcipotriol, tacalcitol, maxacalcitol, and calcitriol;

xxvii. a phytosteroid or a phytosterol;

xxviii. a steroid derived or extracted from one of the families of phytosteroids, phytosterols, phytostanols, ecdysones, withanolids, sterines, steroid saponins and soflavonoids;

xxix. a steroid selected from the group consisting of alpha-sitosterol, beta-sitosterol, stigmastanol, campesterol, alpha-sitostanol, beta-sitostanol, stigmastanol, campestanol, avenosterol, brassicasterol, desmosterol, chalinosterol, beta-ecdysone, whithaferin A, beta-sitosterine, stigmasterine, campesterine, ergosterine, diosgenin, daidzein, glycitein, genistein, muristerone, poriferasterol, clionasterol, campestanol, and cycloartenol;

xxx. a plant oil or a plant extract, which contains a steroid; and

xxxi. a plant oil or a plant extract, selected from the group consisting of nuts seeds, sprouted seeds and grains (such as alfalfa), St. Mary'"'"'s thistle, ginkgo biloba, saw palmetto, panax, siberian ginseng, foeniculum vulgare, cimicifuga racemosa, licorice root, red clover, sage, sarsaparilla, sassafras, angelica sinensis achillea millefolium, anemone pratensis, angelica sinensis, glycyrrhiza glabra, hypericum perforatum, larrea, panax, piscidia erythrina, plantago psyllium, serenoa repens, symphytum, taraxacum officinale, trifolium pratense, turnera spp., tussilago farfara, valeriana officinalis, viburnum prunifolium, and calendula officinalis.

5. The storable foamable emulsion composition of claim 4, further comprising at least one quiescence agent selected from the group consisting of a stabilizing agent, a polymeric agent, a gelling agent, a viscoelastic agent, a pseuedoplastic or semi-pseudoplastic agent, a resilient agent and a modulating agent and mixtures thereof.

6. The storable foamable emulsion composition of claim 1, wherein the foam demonstrates at least seven of the following properties:

(a) a foam quality of 5-6;

(b) a bioadhesivity to said delivery site, requiring a force of about −

3 g to −

30 g to dislodge said foam from said delivery site;

(c) a bioadhesivity to said delivery site, requiring a force of about −

8 g to about −

25 g to dislodge said foam from said delivery site;

(d) a color of white to off-white;

or a yellowish color;

(e) no odor or faint odor;

or substantially masked odor;

(f) a foam quality of 5-6 after at least one freeze-thaw cycle;

(g) a foam quality of 5-6 after about 3 weeks'"'"' storage at 30°

C.;

(h) a foam quality of 5-6 after about 3 weeks'"'"' storage at 40°

C.; and

(i) a foam quality of 5-6 after about 3 weeks'"'"' storage at 50°

C.;

(j) a collapse time of more than 50 seconds;

(k) a collapse time of more than 120 seconds; and

(l) a collapse time of more than 180 seconds.

7. The storable foamable emulsion composition of claim 6, wherein the foam demonstrates all of said properties.

8. The storable foamable emulsion composition of claim 5, wherein the resilient agent is a viscoelastic material capable of forming a pseudoplastic or semi-pseudoplastic composition.

9. The storable foamable emulsion composition of claim 8, wherein the viscoelastic material comprises an effective amount of at least one polymeric additive selected to form a foamable carrier or composition which is resilient to creaming and or phase separation.

10. The storable foamable emulsion composition of claim 8, wherein the viscoelastic material comprises an effective amount of at least one polymeric additive selected to form a foamable carrier or composition which is shakable and flowable to a sufficient amount to be expelled by a propellant from a canister to form a foam of appropriate quality for topical or mucosal application.

11. The storable foamable emulsion composition of claim 8, wherein the viscoelastic material is at least one polymeric additive selected from the group consisting of polysaccharides, natural polysaccharides, derivatives thereof, modified poysacharides, derivatives thereof, starch, dextrin, glycogen, cellulose and chitin, glycosaminoglycans (GAG'"'"'s), chondroitin sulphate, dermatan sulphate, keratan sulphate, heparan sulphate, heparin, and hyaluronan, amylose and amylopectine, cellulose derivatives, xanthan gum, sodium CMC, methylcellulose, hydroxyl propyl methyl cellulose, carbomer, carbopol, and polycarbophil.

12. The storable foamable emulsion composition of claim 1, wherein the delivery site is a body cavity.

13. The storable foamable emulsion composition of claim 12, wherein said composition is suitable for spreading substantially throughout the body cavity surface, effectively such that the active agent reaches a target area.

14. The storable foamable emulsion composition of claim 13, wherein the body cavity is selected from the group consisting of vagina, rectum, colon, penile urethra, nasal cavity and ear cavity.

15. The storable foamable emulsion composition of claim 14, wherein the body cavity is a vagina, and wherein the foam is adapted to spread substantially throughout the vaginal cavity surface, effectively such that the API reaches the cervix.

16. The storable foamable emulsion composition of claim 15, wherein the foam has a bioadhesivity of at least to said delivery site, requiring a force of about −

3 g to about −

30 g to dislodge said foam from said delivery site.

17. The storable foamable emulsion composition of claim 1, further comprising at least one additional non-steroidal therapeutic agent selected from the group consisting of an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative, vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, benzoyl chloride, calcium hypochlorite, magnesium hypochlorite, an anti-wrinkle agent, a radical scavenger, a metal, silver, a metal oxide, titanium dioxide, zinc oxide, zirconium oxide, iron oxide, silicone oxide, talc, carbon, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent and mixtures thereof.

18. The storable foamable emulsion composition of claim 1, wherein the at least one polymeric agent is selected from the group consisting of a water-soluble cellulose ether and naturally-occurring polymeric material.

19. The storable foamable emulsion composition of claim 18, wherein the water-soluble cellulose ether is selected from the group consisting of methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (Methocel), hydroxyethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethylcellulose, carboxymethylhydroxyethylcellulose, xanthan gum, guar gum, carrageenin gum, locust bean gum and tragacanth gum.

20. The storable foamable emulsion composition of claim 1, comprising:

i. a steroid;

ii. at least one organic carrier selected from a hydrophobic organic carrier, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight;

iii. a surface-active agent;

iv. about 0.01% to about 5% by weight of at least one polymeric agent selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent;

v. water; and

vi. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition,

wherein the composition is an emulsion, which is flowable to a sufficient extent to be expelled by the propellant from a canister to form a bioadhesive foam of appropriate quality for topical, body cavity or mucosal application having a bioadhesivity to said delivery site, requiring a force of about −

3 g to about −

30 g to dislodge said foam from said delivery site.

21. A composition according to claim 1 wherein:

(a) the at least one organic carrier comprises at least one carrier selected from the group consisting of ocytyldodecanol, isopropyl myristate, mineral oil, capric/caprylic triglyceride, silicone, lanolin and glycerin;

(b) the at least one a surface-active agent comprises at least one of, Polysorbate 60, Polysorbate 80, Polyoxyl 100 stearate, PEG 40 stearate, PPG 15 Stearyl Ether, and Ceteareth 20,

(c) the at least one polymeric additive comprises at least one of hypromellose, polycarbophil, carbopol and additionally optionally propylene glycol; and

(d) optionally further comprising a foam adjuvant comprising at least one of cetearyl alcohol, oleyl alcohol, stearyl alcohol and stearic acid.

22. A storable foamable emulsion composition adapted for delivery of an active pharmaceutical ingredient (API) to a delivery site in a subject, the composition comprising:

a) at least one fatty alcohol, at a concentration of about 2% to about 50% by weight;

b) at least one surface-active agent at a concentration of about 0.01% to about 5% by weight;

c) at least one polymeric agent selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, each in a concentration of about 0.01% to about 5% by weight;

d) water;

e) an effective amount of at least one API selected from the group consisting of a steroid, a steroid derivative, a further active agent together with the steroid or derivative thereof and combinations thereof; and

f) a propellant at a concentration of about 3% to about 25% by weight of the total foamable composition,

wherein, at ambient temperature, the storable foamable emulsion composition is shakable, is resistant to centrifugation at about 3000 rpm for about 10 min, is substantially devoid of crystals, is resistant to at least one freeze-thaw cycle and does not phase separate within at least about one month;

wherein the at least one API remains chemically stable for about at least about one month; and

wherein the composition is stored in an aerosol container and upon release expands to form a breakable foam having an average bubble size range of about 30 to about 250 micron.

23. The storable foamable emulsion composition of claim 22, wherein the fatty alcohol includes at least one unsaturated fatty alcohol.

24. A method of treating, alleviating or preventing a disorder of the skin, a body cavity or a mucosal surface, wherein the disorder involves inflammation as one of its etiological factors, which method comprise administering topically to a subject having the disorder in need thereof a therapeutically effective amount of a storable foamable emulsion composition comprising:

a. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight;

b. at least one surface-active agent at a concentration of about 0.01% to about 5% by weight;

c. at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, each in a concentration of about 0.01% to about 5% by weight;

d. water;

e. an effective amount of at least one API selected from the group consisting of a steroid, a steroid derivative, a further active agent together with the steroid or derivative thereof and combinations thereof; and

f. a propellant at a concentration of about 3% to about 25% by weight of the total foamable composition,

wherein, at ambient temperature, the storable foamable emulsion composition is shakable, is resistant to centrifugation at about 3000 rpm for about 10 min, is substantially devoid of crystals, is resistant to at least one freeze-thaw cycle and does not phase separate within at least about one month;

wherein the at least one API remains chemically stable for at least about one month; and

wherein the composition is stored in an aerosol container and upon release expands to form a breakable bioadhesive foam having an average bubble size range of about 30 to about 250 micron.